摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-methoxy-1H-2-benzothiopyran-4(3H)-one | 16994-31-3

中文名称
——
中文别名
——
英文名称
7-methoxy-1H-2-benzothiopyran-4(3H)-one
英文别名
7-methoxyisothiochroman-4-one;7-methoxy-isothiochroman-4-one;7-Methoxy-isothiochroman-4-on;7-Methoxy-1H-isothiochromen-4(3H)-one;7-methoxy-1H-isothiochromen-4-one
7-methoxy-1H-2-benzothiopyran-4(3H)-one化学式
CAS
16994-31-3
化学式
C10H10O2S
mdl
——
分子量
194.254
InChiKey
IQTWAYJTTUMULY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    51.6
  • 氢给体数:
    0
  • 氢受体数:
    3

SDS

SDS:3d97e7e513d79627e166647158d8bd0e
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    7-methoxy-1H-2-benzothiopyran-4(3H)-one potassium hydrogensulfate 、 lithium aluminium tetrahydride 、 作用下, 以 乙醚甲苯 为溶剂, 反应 6.25h, 生成 4-(1-Hydroxyethyl)-7-methoxy-Δ3,4-isothiochroman
    参考文献:
    名称:
    Trehan, I. R.; Kaul, R. L.; Sharma, R. K., Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1982, vol. 21, # 3, p. 197 - 199
    摘要:
    DOI:
  • 作为产物:
    描述:
    m-methoxybenzylmercaptoacetic acid三氯乙酸酐 作用下, 以74%的产率得到7-methoxy-1H-2-benzothiopyran-4(3H)-one
    参考文献:
    名称:
    用三氯乙酸酐进行无溶剂傅-克环化
    摘要:
    摘要 使用 1.1 当量对环境无害的三氯乙酸酐作为唯一的试剂和溶剂,获得了 Friedel-Crafts 环化产物。所得的酮包括苯并噻吩、苯并噻喃、苯并恶英、二苯并噻菌、二苯并恶英和四氢萘酮。
    DOI:
    10.1080/00397910802663394
点击查看最新优质反应信息

文献信息

  • Kappa opioid receptor ligands
    申请人:Frank Ivy Carroll
    公开号:US20060183743A1
    公开(公告)日:2006-08-17
    Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.
    Kappa阿片受体拮抗剂提供了在kappa阿片受体的功能结合测定中产生显著改善的结果,并且这些拮抗剂在治疗通过结合kappa阿片受体得到缓解的疾病状态,如海洛因或可卡因成瘾中的使用。
  • Benzopyranopyrazolyl derivatives for the treatment of inflammation
    申请人:——
    公开号:US05547975A1
    公开(公告)日:1996-08-20
    A class of benzopyranopyrazolyl derivatives is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I ##STR1## wherein A is --(CH.sub.2).sub.m --X--(CH.sub.2).sub.n --; wherein X is S(O).sub.p or O; wherein m is 0 or 1; wherein n is 0 or 1; wherein p is 0 or 1; wherein B is selected from phenyl and five and six membered heteroaryl; wherein R.sup.1 is selected from lower haloalkyl, cyano, formyl, lower alkoxycarbonyl, lower alkoxy, lower N-alkylaminocarbonyl, N-phenylaminocarbonyl, lower N,N-dialkylaminocarbonyl and lower N-alkyl-N-phenylaminocarbonyl; wherein R.sup.2 is phenyl substituted at a substitutable position with a radical selected from lower alkylsulfonyl and sulfamyl; and wherein R.sup.4 is one or more radicals selected from hydrido, halo, lower alkylthio, lower alkylsulfinyl, lower alkyl, cyano, carboxyl, lower alkoxycarbonyl, aminocarbonyl, lower haloalkyl, hydroxyl, lower alkoxy, amino, lower N-alkylamino, lower N,N-dialkylamino, lower hydroxyalkyl and lower haloalkoxy; or a pharmaceutically-acceptable salt thereof.
    描述了一类苯并吡喁啉衍生物用于治疗炎症和与炎症相关的疾病。特别感兴趣的化合物由以下式I定义:其中A为--(CH.sub.2).sub.m --X--(CH.sub.2).sub.n --;其中X为S(O).sub.p或O;其中m为0或1;其中n为0或1;其中p为0或1;其中B选自苯基和五元和六元杂芳基;其中R.sup.1选自低卤代烷基、氰基、甲酰基、低烷氧羰基、低烷氧基、低N-烷基氨基羰基、N-苯基氨基羰基、低N,N-二烷基氨基羰基和低N-烷基-N-苯基氨基羰基;其中R.sup.2为苯基,在可取代位置上取代基为低烷基磺酰基和磺胺基;其中R.sup.4为一个或多个基团,选自氢、卤素、低烷基硫基、低烷基亚硫酰基、低烷基、氰基、羧基、低烷氧羰基、氨基羰基、低卤代烷基、羟基、低烷氧基、氨基、低N-烷基氨基、低N,N-二烷基氨基、低羟基烷基和低卤代氧基;或其药用可接受的盐。
  • [EN] BENZOPYRANOPYRAZOLYL DERIVATIVES FOR THE TREATMENT OF INFLAMMATION<br/>[FR] DERIVES DE BENZOPYRANOPYRAZOLYLE POUR LE TRAITEMENT DES INFLAMMATIONS
    申请人:G.D. SEARLE & CO.
    公开号:WO1996009304A1
    公开(公告)日:1996-03-28
    (EN) A class of benzopyranopyrazolyl derivatives is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by formula (I) wherein A is -(CH2)m-X-(CH2)n-; wherein X is S(O)p or O; wherein m is 0 or 1; wherein n is 0 or 1; wherein p is 0 or 1; wherein B is selected from phenyl and five and six membered heteroaryl; wherein R1 is selected from lower haloalkyl, cyano, lower hydroxyalkyl, formyl, lower alkoxycarbonyl, lower alkoxy, lower N-alkylaminocarbonyl, N-phenylaminocarbonyl, lower N,N-dialkylaminocarbonyl and lower N-alkyl-N-phenylaminocarbonyl; wherein R2 is phenyl substituted at a substitutable position with a radical selected from lower alkylsulfonyl and aminosulfonyl; and wherein R4 is one or more radicals selected from hydrido, halo, lower alkylthio, lower alkylsulfinyl, lower alkyl, cyano, carboxyl, lower alkoxycarbonyl, aminocarbonyl, lower haloalkyl, hydroxyl, lower alkoxy, amino, lower N-alkylamino, lower N,N-dialkylamino, lower hydroxyalkyl and lower haloalkoxy; or a pharmaceutically-acceptable salt thereof.(FR) L'invention concerne une classe de dérivés de benzopyranopyrazolyle destinés à être utilisés dans le traitement des inflammations et les troubles apparentés à une inflammation. Les composés présentant un intérêt particulier répondent à la formule (I) dans laquelle: A représente -(CH2)m -X-(CH2)n, où X représente S(Op) ou O, m vaut 0 ou 1, n vaut 0 ou 1, et p vaut 0 ou 1; B est choisi entre phényle et un groupe hétéroaryle à cinq ou six chaînons; R1 est choisi parmi haloalkyle inférieur, cyano, hydroxyalkyle inférieur, formyle, alcoxycarbonyle inférieur, alcoxy inférieur, N-alkylaminocarbonyl inférieur, N-phénylaminocarbonyle, N,N-dialkylaminocarbonyl inférieur et N-alkyl-N-phénylaminocarbonyl inférieur; R2 représente un phényle substitué dans une position de substitution par un radical choisi entre alkysulfonyle inférieur et aminosulfonyle; et R4 représente un ou plusieurs radicaux appartenant au groupe hybrido, halo, alkylthio inférieur, alkylsufinyle inférieur, alkyle inférieur, cyano, carboxyl, alcoxycarbonyl inférieur, aminocarbonyl, haloalkyle inférieur, hydroxyle, alcoxy inférieur, amino, N-alkylamino inférieur, N,N-dialkylamino inférieur, hydroxyalkyl inférieur et haloalcoxy inférieur. L'invention concerne également un sel pharmaceutiquement acceptable desdits dérivés.
    描述了一类苯并吡唑基衍生物,用于治疗炎症和与炎症相关的疾病。特别感兴趣的化合物由式(I)定义,其中A为-(CH2)m-X-(CH2)n-;其中X为S(O)p或O;其中m为0或1;其中n为0或1;其中p为0或1;其中B选自苯基和五元和六元杂环基;其中R1选自低卤代烷基、氰基、低羟基烷基、甲酰基、低烷氧羰基、低烷氧基、低N-烷基氨基羰基、N-苯基氨基羰基、低N,N-二烷基氨基羰基和低N-烷基-N-苯基氨基羰基;其中R2为苯基,在可取代位置上用从低烷基磺酰基和氨基磺酰基中选择的基团取代;其中R4为一个或多个从氢、卤素、低烷基硫基、低烷基亚磺酰基、低烷基、氰基、羧基、低烷氧羰基、氨基羰基、低卤代烷基、羟基、低烷氧基、氨基、低N-烷基氨基、低N,N-二烷基氨基、低羟基烷基和低卤代烷氧基中选择的基团;或其药学上可接受的盐。
  • Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2
    申请人:Pharmacia Corporation
    公开号:US20040127492A1
    公开(公告)日:2004-07-01
    Cyclic pyrazole compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of making such compounds are described, as well as a method of using them for the inhibition of MK-2 in a subject in need of such inhibition, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.
    本发明涉及一种环状吡唑化合物,其能够抑制丝裂原活化蛋白激酶激活蛋白激酶-2(MK-2)。本发明还描述了制备这种化合物的方法,以及一种使用它们来抑制需要这种抑制的受体的方法,其中该方法涉及向受体中注射本发明的MK-2抑制化合物。本发明还描述了包含本MK-2抑制化合物的药物组合物和工具箱。
  • Pyrazolyl derivatives for the treatment of inflammation
    申请人:G. D. Searle & Co.
    公开号:US05670532A1
    公开(公告)日:1997-09-23
    A class of benzopyranopyrazolyl derivatives is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I ##STR1## wherein A is --(CH.sub.2).sub.m --X--(CH.sub.2).sub.n --; wherein X is S(O).sub.p or O; wherein m is 0 or 1; wherein n is 0 or 1; wherein p is 0 or 1; wherein B is selected from phenyl and five and six membered heteroaryl; wherein R.sup.1 is selected from lower haloalkyl, cyano, formyl, lower alkoxycarbonyl, lower alkoxy, lower N-alkylaminocarbonyl, N-phenylaminocarbonyl, lower N,N-dialkylaminocarbonyl and lower N-alkyl-N-phenylaminocarbonyl; wherein R.sup.2 is phenyl substituted at a substitutable position with a radical selected from lower alkylsulfonyl and sulfamyl; and wherein R.sup.4 is one or more radicals selected from hydrido, halo, lower alkylthio, lower alkylsulfinyl, lower alkyl, cyano, carboxyl, lower alkoxycarbonyl, aminocarbonyl, lower haloalkyl, hydroxyl, lower alkoxy, amino, lower N-alkylamino, lower N,N-dialkylamino, lower hydroxyalkyl and lower haloalkoxy; or a pharmaceutically-acceptable salt thereof.
    本发明涉及一类苯并吡唑衍生物,用于治疗炎症和与炎症相关的疾病。特别感兴趣的化合物由公式I定义,其中A是--(CH2)m--X--(CH2)n--; X为S(O)p或O; m为0或1; n为0或1; p为0或1; B选自苯基和五元和六元杂环基; R1选自较低的卤代烷基,氰基,甲酰基,较低的烷氧羰基,较低的烷氧基,较低的N-烷基氨基羰基,N-苯基氨基羰基,较低的N,N-二烷基氨基羰基和较低的N-烷基-N-苯基氨基羰基; R2是苯基,在可取代位置上用较低的烷基磺酰基和磺酰胺基中的一种基团取代; R4是一个或多个基团,选自氢,卤,较低的烷基硫醇,较低的烷基亚磺酰基,较低的烷基,氰基,羧基,较低的烷氧羰基,氨基羰基,较低的卤代烷基,羟基,较低的烷氧基,氨基,较低的N-烷基氨基,较低的N,N-二烷基氨基,较低的羟基烷基和较低的卤代氧基; 或其药学上可接受的盐。
查看更多

同类化合物

6-溴-3,4-二氢-2H-异硫代色烯-4-胺盐酸盐 6-溴-3,4-二氢-1H-S,S-二氧代异硫色烯-4-氨基盐酸盐 4-氨基异硫代苯并二氢吡喃2,2-二氧化物盐酸盐 3,4-二氢-1H-异硫苯并吡喃-4-胺盐酸盐 3,4-二氢-1H-S,S-二-氧代-异硫基苯并吡喃-4-胺盐酸盐 3,4-二氢-1H-2-苯并噻喃 2-异硫代苯并二氢吡喃-4-酮 1H-2-苯并噻喃-4-醇,3,4-二氢- (9ci)-3,4-二氢-1H-2-苯并硫代吡喃-1-羰酰氯 (4r)-(9ci)-6-乙基-3,4-二氢-1H-2-苯并硫代吡喃-4-胺,2,2-二氧化物 4-amino-1-(3,3-dimethylisothiochroman-4-yl)-5-imidazolecarboxylic acid methyl ester methyl 5,8-dimethoxyisothiochroman-3-carboxylate 1-(2'-Dimethylaminopropyl)-1-ethylsulfonyl-isothiochroman-S,S-dioxid N-diethoxyphosphoryl-6,7-dimethyl-3,4-dihydro-1H-2-benzothiopyran-4-one-1-carboxamide 1-(3,3-dimethylisothiochroman-4-yl)-5-imidazolecarboxylic acid methyl ester 4-methyl-isothiochroman-2,2-dioxide 1-(α-methoxybenzylidene)-3,4-dihydro-1H-2-thianaphthalene 3-methyl-isothiochroman-4-one 1,3-dimethyl-1H-2-benzothiopyran-4-(3H)-one 8-Oxo-1,2,3,5,7,8-hexahydro-6-thia-cyclopenta[b]naphthalene-5-carboxylic acid ethyl isothiochroman-1-carboxylate 1-<(3,4-dihydro-1H-2-benzothiopyran-3-yl)acetyl>-1H-indole 7-Methoxy-3-phenyl-4-isothiochromanon 4-oxo-isothiochroman-3-carboxylic acid methyl ester 7-methoxy-isothiochroman-4-ol 8-methylisothiochroman-4-one 1-cyano-1-methylisothiochroman ethyl 6,7-dimethyl-3,4-dihydro-1H-2-benzothiopyran-4-one-1carboxylate 4-diazoisothiochroman-3-one 3,4-dihydro-3,3-dimethyl-1H-2-thianaphthalene 3,6-dithiaoctahydrophenanthrene-1,8-dione 3,6-dithia-3,4,5,6,7,8-hexahydrophenanthrene[1,2-d][1,2,3]selenadiazol-8-one (S)-(+)-4-ethyl-3,4-dihydro-1H-2-benzothiine 5-chloro-3,4-dihydro-1H-2-benzothiopyran 5-chloro-3,4-dihydro-1H-2-benzothiopyran 2,2-dioxide 8-oxo-5H-thiopyrano[4,3-f][1,3]benzodioxole-5-carboxylic acid 8-phenylisothiochroman-1-one N-<4-(diethoxyphosphorylmethyl)phenyl>-6-cyclohexyl-3,4-dihydro-4-oxo-1H-2-benzothiopyran-1-carboxamide 7-methoxy-isothiochroman-3-carbonyl chloride ethyl 3,4-dihydrospiro(1H-2-benzothiopyran-1,4'-piperidine)-1'-carboxylate 3,4-dihydrospiro(1H-2-benzothiopyran-1,4'-piperidine) 3,4-dihydrospiro(1H-2-benzothiopyran-1,4'-piperidine) 2-oxide 8-Chloroisothiochroman-4-one 1-(3-nitrophenyl)-3,4-dihydro-1H-isothiochromene 7-Chlor-isothiochroman-4-on 3-acetyl-5,8-dimethoxyisothiochroman isothiochroman-4-ylamine 5-methyl-3,4-dihydro-1H-2-benzothiopyran-1-one 2-ethyl-4-oxoisothiochromanium tetrafluoroborate 3,7-dithiaoctahydroanthracene-1,5-dione